Dr. Westin will focus on known molecular abnormalities that have allowed the field of precision medicine blossom in ovarian cancer.
Novel targeted therapies including PARP inhibitors and anti-angiogenics will be featured.
We thank Merck for their generous support of this program.
December 12, 2017 1:00 PM Eastern
1 hour, 30 minutes